Increasing resistance to antibiotics worldwide has adverse effects on the effectiveness of
standard therapies to eradicate Helicobacter pylori infection. We reviewed guidelines …

Parietal cells are responsible for gastric acid secretion, which aids in the digestion of food,
absorption of minerals, and control of harmful bacteria. However, a fine balance of activators …

This review summarizes important studies regarding Helicobacter pylori therapy published
from April 2019 to April 2020. The main themes that emerge involve studies assessing …

Background Potassium‐competitive acid blockers (P‐CAB) are recommended for the
treatment of Helicobacter pylori infections, but dual therapy of P‐CAB with amoxicillin has …

Conventional proton pump inhibitors (PPIs) are used as a first-line therapy to treat acid-
related diseases worldwide. However, they have a number of limitations including slow …

The main challenge in the field of Helicobacter pylori (H. pylori) infection is antibiotic
resistance, which influences the efficacy of eradication regimens. Bismuth-containing …

Background Vonoprazan is a novel gastric acid suppressant that is applied in Japan to treat
gastric diseases including Helicobacter pylori (H. pylori) infection. This meta‐analysis aimed …

Background Vonoprazan‐amoxicillin (VA) dual therapy has been shown to achieve
acceptable cure rates for treatment of Helicobacter pylori (H. pylori) in Japan. Its …

The strategic fluorination of oxidatively vulnerable sites in bioactive compounds is a
relatively recent, widely used approach allowing us to modulate the stability, bio-absorption …

Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …